The functional validity of any peptide-based preclinical experiment depends on knowing what is actually in the vial. Purity by HPLC and identity by mass spectrometry are not bureaucratic QC checkboxes — they are the analytical foundation upon which pharmacological interpretation rests. Lot-to-lot analytical consistency is what separates a vendor supplying a research material from one supplying an undefined biological reagent.
Reversed-Phase HPLC: Quantifying Main Component Purity
Reversed-phase HPLC (RP-HPLC) on C18 stationary phase with UV detection at 214 nm (peptide bond absorption) is the primary method for quantifying main component purity. Detection at 214 nm provides uniform sensitivity across all peptide sequences regardless of aromatic residue content, while 280 nm is restricted to sequences containing Trp or Tyr. A gradient of 0.1% TFA in water vs. 0.1% TFA in acetonitrile (or equivalent acetonitrile/water with 0.1% formic acid for MS-compatible runs) resolves main component from deletion sequences, oxidized species, and aggregates differing by 0.5–1% in acetonitrile content. The area percent of the main peak relative to all integrated peaks defines chromatographic purity. A specification of ≥99% by this method for research-grade material is appropriate; material at 95–98% is acceptable for screening studies but insufficient for quantitative dose-response work where EC50 determination requires accurate molar concentrations. Photodiode array (DAD) detection adds spectral purity verification — a non-peptide co-eluting contaminant will show a distinct UV absorption spectrum from the main peak.
Mass Spectrometry Identity Confirmation
HPLC purity establishes the quantity of main component but does not confirm its identity. ESI-MS (electrospray ionization mass spectrometry) is the standard identity confirmation method for synthetic peptides up to ~5,000 Da. ESI-MS generates multiply charged ions ([M+nH]n+), requiring deconvolution software to extract the monoisotopic or average mass. The observed mass should match the theoretical monoisotopic mass within ±0.5 Da (for peptides <2,000 Da) or within ±1 Da (for peptides 2,000–5,000 Da). Discrepancies indicate truncation sequences, miscoupling, incomplete deprotection (+OH additions), or oxidation (+16 Da per Met or Cys residue). MALDI-TOF is an alternative for larger peptides and provides rapid [M+H]+ confirmation with matrix-dependent mass accuracy of 0.01–0.1%. MS/MS fragmentation (either CID or HCD) provides sequence-level confirmation by generating b- and y-ion series, which is required for novel peptides where no reference standard exists. Alpha Nordisk provides full ESI-MS spectra with observed vs. theoretical mass comparison in all lot CoAs.
Endotoxin Testing and Bioburden
For research peptides used in cell-based assays or in vivo rodent studies, endotoxin content is a critical variable. Lipopolysaccharide (LPS) contamination at concentrations as low as 0.1 EU/mL activates TLR4 signaling in macrophages, confounding cytokine readouts, NF-κB reporter assays, and inflammatory endpoint measurements. The Limulus Amebocyte Lysate (LAL) assay (chromogenic or turbidimetric endpoint) is the standard method, with an acceptance criterion of <1 EU/mg for research-grade material used in cell culture. Recombinant Factor C (rFC) assay is an endotoxin-specific alternative free of horseshoe crab lysate variability. Peptide matrix effects on LAL assays (positively charged peptides can interfere with gelation) require spike-recovery validation at the test concentration.
Net Peptide Content and Lot Documentation Minimum Requirements
Net peptide content (NPC) — measured by amino acid analysis (AAA) following acid hydrolysis (6M HCl, 110°C, 24 h) or by quantitative UV at 280 nm for Trp/Tyr-containing sequences — corrects for water content (typically 5–15% w/w) and counterion mass (TFA contributes ~114 Da per molecule; acetate ~59 Da). A certificate of analysis lacking NPC provides insufficient information for accurate molar dosing. Minimum lot documentation for preclinical research use should include: sequence, molecular formula, MW, HPLC purity (%), NPC (%), counterion identity, water content (%), MS data (observed vs. theoretical), endotoxin (EU/mg), storage conditions, and lot number with manufacturing date. Alpha Nordisk provides all these parameters as standard documentation on every released lot.
Alpha Nordisk presents this content for research documentation purposes. All products referenced are for research and laboratory use only. Not for unsupervised human consumption.